WO2024229461A3 - Anticorps anti-cd161 et leurs procédés d'utilisation - Google Patents

Anticorps anti-cd161 et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2024229461A3
WO2024229461A3 PCT/US2024/028001 US2024028001W WO2024229461A3 WO 2024229461 A3 WO2024229461 A3 WO 2024229461A3 US 2024028001 W US2024028001 W US 2024028001W WO 2024229461 A3 WO2024229461 A3 WO 2024229461A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
same
methods
antigen
bind
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/028001
Other languages
English (en)
Other versions
WO2024229461A2 (fr
Inventor
Jiayi YU
Sanjay RATHOD
Krishnadatt Persaud
Mani MOHINDRU
Pallavi TAWDE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novasenta Inc
Original Assignee
Novasenta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novasenta Inc filed Critical Novasenta Inc
Priority to AU2024265613A priority Critical patent/AU2024265613A1/en
Priority to EP24728442.5A priority patent/EP4705342A2/fr
Priority to KR1020257033884A priority patent/KR20260007566A/ko
Priority to CN202480026299.XA priority patent/CN121079326A/zh
Publication of WO2024229461A2 publication Critical patent/WO2024229461A2/fr
Publication of WO2024229461A3 publication Critical patent/WO2024229461A3/fr
Priority to IL323244A priority patent/IL323244A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps et des parties de liaison à l'antigène de ceux-ci qui se lient à CD161, des anticorps bispécifiques et des anticorps multispécifiques comprenant ceux-ci, des acides nucléiques et des vecteurs codant pour ceux-ci, et des procédés d'utilisation de ceux-ci pour traiter un sujet qui en a besoin.
PCT/US2024/028001 2023-05-04 2024-05-06 Anticorps anti-cd161 et leurs procédés d'utilisation Ceased WO2024229461A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2024265613A AU2024265613A1 (en) 2023-05-04 2024-05-06 Anti-cd161 antibodies and methods of use thereof
EP24728442.5A EP4705342A2 (fr) 2023-05-04 2024-05-06 Anticorps anti-cd161 et leurs procédés d'utilisation
KR1020257033884A KR20260007566A (ko) 2023-05-04 2024-05-06 항-cd161 항체 및 이의 사용 방법
CN202480026299.XA CN121079326A (zh) 2023-05-04 2024-05-06 抗cd161抗体及其使用方法
IL323244A IL323244A (en) 2023-05-04 2025-09-08 Antibodies against CD161 and methods of using them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363500122P 2023-05-04 2023-05-04
US63/500,122 2023-05-04

Publications (2)

Publication Number Publication Date
WO2024229461A2 WO2024229461A2 (fr) 2024-11-07
WO2024229461A3 true WO2024229461A3 (fr) 2024-12-26

Family

ID=91248035

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/028001 Ceased WO2024229461A2 (fr) 2023-05-04 2024-05-06 Anticorps anti-cd161 et leurs procédés d'utilisation

Country Status (7)

Country Link
EP (1) EP4705342A2 (fr)
KR (1) KR20260007566A (fr)
CN (1) CN121079326A (fr)
AU (1) AU2024265613A1 (fr)
IL (1) IL323244A (fr)
TW (1) TW202509069A (fr)
WO (1) WO2024229461A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021080682A1 (fr) * 2019-10-24 2021-04-29 Massachusetts Institute Of Technology Anticorps monoclonaux qui se lient au cd161 humain et leurs utilisations
US20210363260A1 (en) * 2017-11-13 2021-11-25 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
WO2023028501A1 (fr) * 2021-08-23 2023-03-02 Immunitas Therapeutics, Inc. Anticorps anti-cd161 et leurs utilisations

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (fr) 2005-07-01 2018-11-06 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
JP2012500652A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
EP4209510B1 (fr) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
SI2480675T1 (sl) 2010-06-22 2016-08-31 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo lahko verigo s spremenljivo regijo humanega lambda in konstantno mišjo regijo
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
US11312783B2 (en) 2017-06-22 2022-04-26 Novartis Ag Antibody molecules to CD73 and uses thereof
US10738128B2 (en) 2018-03-14 2020-08-11 Surface Oncology, Inc. Antibodies that bind CD39 and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210363260A1 (en) * 2017-11-13 2021-11-25 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
WO2021080682A1 (fr) * 2019-10-24 2021-04-29 Massachusetts Institute Of Technology Anticorps monoclonaux qui se lient au cd161 humain et leurs utilisations
WO2023028501A1 (fr) * 2021-08-23 2023-03-02 Immunitas Therapeutics, Inc. Anticorps anti-cd161 et leurs utilisations

Also Published As

Publication number Publication date
CN121079326A (zh) 2025-12-05
AU2024265613A1 (en) 2025-09-25
WO2024229461A2 (fr) 2024-11-07
KR20260007566A (ko) 2026-01-14
TW202509069A (zh) 2025-03-01
IL323244A (en) 2025-11-01
EP4705342A2 (fr) 2026-03-11

Similar Documents

Publication Publication Date Title
WO2021018859A3 (fr) Anticorps se liant à gprc5d
PH12020551211A1 (en) Antibodies binding to gprc5d
NZ774111A (en) Antibodies binding to cd3
JOP20200213A1 (ar) جزيئات رابطة لـ pd-1 وطرق استخدامها
HK1252827A1 (zh) 结合lag-3的分子和其使用方法
AU2018275359A1 (en) Antibodies specific for FLT3 and their uses
PH12020551153A1 (en) Antibodies specific for cd70 and their uses
WO2018017786A3 (fr) Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations
WO2018013818A3 (fr) Anticorps anti-tim3 et leurs utilisations
MX2016005765A (es) Anticuerpos anti-il-17, un metodo para producir y utilizar los mismos.
PH12019502274A1 (en) Antibodies binding to steap-1
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
PH12022500027A1 (en) Antibodies binding to cd3
EP4691565A3 (fr) Anticorps bispécifique et son utilisation
MX2024015072A (es) Anticuerpos anti-egfr/met y usos de los mismos
WO2023138551A9 (fr) Anticorps bispécifique anti-cd3 et anti-cd20 et son utilisation
WO2021231651A8 (fr) Constructions d'anticorps à domaine unique neutralisant le sars-cov2
EP4268842A3 (fr) ANTICORPS BISPÉCIFIQUE DIRIGÉ CONTRE a-SYN/IGF1R ET UTILISATION ASSOCIÉE
MX2024004563A (es) Complejo polipeptidico activable.
SG11202101608XA (en) Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof
WO2024182317A3 (fr) Fusions multivalentes d'anticorps à piège
AU2024396207A1 (en) Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
HK40112297A (en) Bispecific binding agents binding to cldn18.2 and cd3
MX2025008548A (es) Agentes de union nkg2a y usos de estos
MX2025008617A (es) Agentes que se unen a nkg2a y pd-l1 y usos de estos

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24728442

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2024265613

Country of ref document: AU

Ref document number: 323244

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2024265613

Country of ref document: AU

Date of ref document: 20240506

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2025558695

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025558695

Country of ref document: JP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025022844

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202517120496

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2024728442

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024728442

Country of ref document: EP

Effective date: 20251204

ENP Entry into the national phase

Ref document number: 2024728442

Country of ref document: EP

Effective date: 20251204

WWP Wipo information: published in national office

Ref document number: 202517120496

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2024728442

Country of ref document: EP

Effective date: 20251204

ENP Entry into the national phase

Ref document number: 2024728442

Country of ref document: EP

Effective date: 20251204

ENP Entry into the national phase

Ref document number: 2024728442

Country of ref document: EP

Effective date: 20251204

ENP Entry into the national phase

Ref document number: 2024728442

Country of ref document: EP

Effective date: 20251204

ENP Entry into the national phase

Ref document number: 2024728442

Country of ref document: EP

Effective date: 20251204

ENP Entry into the national phase

Ref document number: 2024728442

Country of ref document: EP

Effective date: 20251204

WWP Wipo information: published in national office

Ref document number: 2024728442

Country of ref document: EP